Deciphering potential molecular mechanisms in clear cell renal cell carcinoma based on the ubiquitin‐conjugating enzyme E2 related genes: Identifying UBE2C correlates to infiltration of regulatory T cells

Abstract Renal clear cell carcinoma (ccRCC) is a highly aggressive and common form of kidney cancer, with limited treatment options for advanced stages. Recent studies have highlighted the importance of the ubiquitin‐proteasome system in tumor progression, particularly the role of ubiquitin‐conjugating enzyme E2 (UBE2) family members. However, the prognostic significance of UBE2‐related genes (UBE2RGs) in ccRCC remains unclear. In this study, bulk RNA‐sequencing and single‐cell RNA‐sequencing data from ccRCC patients were retrieved from the Cancer Genome Atlas and Gene Expression Omnibus databases. Differential expression analysis was performed to identify UBE2RGs associated with ccRCC. A combination of 10 machine learning methods was applied to develop an optimal prognostic model, and its predictive performance was evaluated using area under the curve (AUC) values for 1‐, 3‐, and 5‐year overall survival (OS) in both training and validation cohorts. Functional enrichment analyses of gene ontology and Kyoto Encyclopedia of Genes and Genomes were conducted to explore the biological pathways involved. Correlation analysis was conducted to investigate the association between the risk score and tumor mutational burden (TMB) and immune cell infiltration. Immunotherapy and chemotherapy sensitivity were assessed by immunophenoscore and tumor immune, dysfunction, and exclusion scores to identify potential predictive significance. In vitro, knockdown of the key gene UBE2C in 786‐O cells by specific small interfering RNA to validate its impact on apoptosis, migration, cell cycle, migration, invasion of tumor cells, and induction of regulatory T cells (Tregs). Analysis of sc‐RNA revealed that UBE2 activity was significantly upregulated in malignant cells, suggesting its role in tumor progression. A three‐gene prognostic model comprising UBE2C, UBE2D3, and UBE2T was constructed by Lasoo Cox regression and demonstrated robust predictive accuracy, with AUC values of 0.745, 0.766, and 0.771 for 1‐, 3‐, and 5‐year survival, respectively. The model was validated as an independent prognostic factor in ccRCC. Patients in the high‐risk group had a worse prognosis, higher TMB scores, and low responsiveness to immunotherapy. Additionally, immune infiltration and chemotherapy sensitivity analyses revealed that UBE2RGs are associated with various immune cells and drugs, suggesting that UBE2RGs could be a potential therapeutic target for ccRCC. In vitro experiments confirmed that the reduction of UBE2C led to an increase in apoptosis rate, as well as a decrease in tumor cell invasion and metastasis abilities. Additionally, si‐UBE2C cells reduced the release of the cytokine Transforming Growth Factor‐beta 1 (TGF‐β1), leading to a decreased ratio of Tregs in the co‐culture system. This study presents a novel three‐gene prognostic model based on UBE2RGs that demonstrates significant predictive value for OS, immunotherapy, and chemotherapy in ccRCC patients. The findings underscore the potential of UBE2 family members as biomarkers and therapeutic targets in ccRCC, warranting further investigation in prospective clinical trials.